This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Medimmune Limited. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Innovations by Marcella Petrone in Obesity Treatment
Introduction
Marcella Petrone is a notable inventor based in Cambridge, GB. She has made significant contributions to the field of obesity treatment through her innovative research and development. Her work focuses on the use of GLP-1 and glucagon co-agonists, which have the potential to transform the management of obesity and diabetes.
Latest Patents
Marcella holds 1 patent for her invention titled "Glucagon and GLP-1 co-agonists for the treatment of obesity." This patent outlines methods for preventing and treating obesity and diabetes in patients by administering GLP-1/glucagon agonist peptides. Her innovative approach aims to provide effective solutions for individuals struggling with these health issues.
Career Highlights
Marcella is currently associated with Medimmune Limited, where she continues to advance her research in the field of obesity treatment. Her dedication to innovation and her expertise in peptide therapies have positioned her as a key figure in her area of specialization.
Collaborations
Throughout her career, Marcella has collaborated with esteemed colleagues, including Maria Aleksandra Bednarek and Lutz Jermutus. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking treatments.
Conclusion
Marcella Petrone's contributions to the field of obesity treatment through her innovative patent demonstrate her commitment to improving patient outcomes. Her work continues to inspire advancements in medical research and therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile